TAVR in Intermediate-Risk Patients: Is It as Effective as Surgical Aortic Valve Replacement?

Courtesy of Dr. Carlos Fava.

surgical aortic valve replacement.Transcatheter aortic valve replacement (TAVR) has proven to be beneficial for extreme- and high-risk patients. It is also increasingly used in intermediate-risk patients, and it has been hinted at for low-risk patients. However, different sectors in the medical community still challenge the existence of real TAVR benefit.

 

This assessment consisted in a meta-analysis including data from 7 trials (2 of them randomized trials) with intermediate-risk patients who presented severe aortic stenosis. This study included 4601 patients; 2305 subjects who underwent TAVR, and 2296 who underwent surgical aortic valve replacement.

 

There were no significant differences in 30-day all-cause mortality among groups.

 

Follow-up at 1.15 years showed no significant difference in all-cause death, acute myocardial infarction, and stroke. TAVR resulted in lower rates of acute kidney injury (4.6% vs. 8.1%; odds ratio [OR]: 0.53; 95% confidence interval [CI]: 0.38-0.74; number needed to treat [NNT] = 26; p = <0.001; I2 = 35%), major bleeding (18.1% vs. 44.6%; 0.54; 95% CI: 0.31-0.93; NNT = 4; p = 0.03; I2 = 82%), and new atrial fibrillation (10.9% vs. 26.7%; risk ratio [RR]: 0.41; 95% CI: 0.33-0.50; NNT =  6; p > 0.001). However, it also resulted in higher rates of major vascular complications (8.5% vs. 3.1%; RR: 7.87; 95% CI: 1.49-41.69; number needed to harm (NNH) = 1; p = 0.02; I2 = 83%), permanent pacemaker implantation (13.5% vs. 7.7%; RR: 2.26; 95% CI: 1.20-4.27; NNH = 17; p = 0.01, I2 = 77%), and moderate/severe aortic regurgitation (13.3% vs. 8.9%; RR: 6.93; 95% CI: 3.28-14.64; NNH = 13; p < 0.001; I2 = 27%).

 

The rate of permanent pacemaker implantation was significantly higher with TAVR in observational studies than in randomized studies.

 

Conclusion

This analysis of mid-term results showed that TAVR has similar clinical efficacy to surgical aortic valve replacement in intermediate-risk patients with severe aortic stenosis, and can be a suitable alternative to surgical aortic valve replacement.

 

Editorial Comment

While these results encourage the use of TAVR in intermediate-risk patients, mid-term follow-up is still the limit. The behavior of valves at 10 years or longer remains unknown, since expected survival for this group is much longer than for high- or prohibitive-risk patients.

 

These patients need to be monitored over time, and technology for the reduction of complications must be developed (particularly for cases in which surgery is still better than TAVR), so that we can offer a global solution to our patients.

 

Courtesy of Dr. Carlos Fava.

 

Original title: Transcatheter Versus Surgical Aortic Valve Replacement in Intermediate-Risk Patients: Evidence from a Meta-Analysis

Partha Sardar et al. Catheterization and Cardiovasc Intev 2017 Early View

 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...